Mazdutide: Dual-Agonist Evidence and Phase 3 Context

A distinct dual-agonist program

Mazdutide, also known by the development code IBI362, is designed to activate GLP-1 and glucagon receptors. That pairing differs from tirzepatide, which engages GIP and GLP-1 receptors, and from retatrutide, which engages three receptor systems. Shared discussion within incretin research does not make the molecules interchangeable.

The biological rationale combines GLP-1-related metabolic signaling with glucagon-receptor activity. A pathway diagram can explain that design, but observed benefit and risk must come from trials of the defined molecule.

What controlled studies contribute

Phase 1b and phase 2 randomized studies in China reported changes in body weight and metabolic measures in their enrolled populations. These trials provide human evidence rather than a purely preclinical signal. Their conclusions remain tied to eligibility criteria, comparators, follow-up, analysis methods, and the adverse events that were collected.

Larger phase 3 programs are intended to test the findings in broader and more definitive settings. Until those results and regulatory decisions are complete, it is too early to treat the program as settled or to assume that findings from another incretin medicine apply to mazdutide.

Cross-trial rankings are unreliable

Percent change from separate trials cannot establish a winner when populations, duration, estimands, background care, discontinuation rules, and missing-data methods differ. A credible comparison requires a direct trial or a carefully justified comparative method.

This article summarizes the development evidence and does not provide titration, administration, sourcing, combination, or personal treatment guidance. Regulatory status is specific to product, indication, country, and date. Educational content only. Not medical advice.

Educational content only. Not medical advice.

Continue with source-linked research guides